Kos Seeks Court Order to Block Launch of Generic Niaspan
Kos Pharmaceuticals has filed a lawsuit to block Barr Pharmaceuticals from launching generic versions of Kos' cholesterol-lowering drug Niaspan upon the expiration of a 30-month stay of approval by the U.S....To view the full article, register now.
Already a subscriber? Click here to view full article